Xiawei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiawei Li has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Yulian Wu
Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 shared publications Sien Hu
Department of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
5 shared publicationsYongji Sun
Department of Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 shared publicationsTianyu Song
Department of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
4 shared publicationsChangming Lv
Department of General Surgery, The First People’s Hospital of Jiande, Hangzhou, China
3 shared publicationsJian Wu
3 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in npj Digital Medicine
Automated pancreatic cancer pathology image segmentation using deep learning to quantify lymphocyte stroma ratio
- 15 September 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessAutomated pancreatic cancer pathology image segmentation using deep learning to quantify lymphocyte stroma ratio
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 247
Plasma fatty acid associated with risk of gastrointestinal cancer: a prospective cohort study from UK Biobank
Background: Gastrointestinal (GI) cancers represent a leading cause of cancer-related mortality worldwide, highlighting an urgent need for effective preventive approaches. While fatty acids (FAs) are implicated of carcinogenesis across multiple cancer types, their specific associations with GI cancer risk, and particularly their clinical utility as actionable biomarkers for risk stratification and personalized prevention within existing preventive frameworks, remain poorly understood. This study aimed to prospectively assess these associations and evaluate the clinical utility of plasma fatty acids for risk stratification and personalized prevention. Methods: This prospective cohort study included 91,239 cancer-free UK Biobank participants at baseline [2006–2010]. Plasma FAs were quantified using nuclear magnetic resonance (NMR) spectroscopy. Incident GI cancers [esophagus, stomach, colorectum, liver, bile duct, pancreas; International Classification of Diseases 10 (ICD-10) codes] were identified via national cancer registries through 2020. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) for incident GI cancers, with comprehensive adjustment for sociodemographic, lifestyle, and clinical covariates. Results: During a median follow-up of 11.8 years, 1,519 incident GI cancer cases were documented. Compared to non-cases, cases were older (mean age 60.8 vs. 55.5 years) and had a higher proportion of males (58.2% vs. 45.8%). After comprehensive adjustment for sociodemographic factors [age, sex, family history, educational level, Townsend deprivation index (TDI)], lifestyle characteristics (smoking, alcohol consumption, lifestyle score), clinical covariates [body mass index (BMI), diabetes history], and mutual correction for FA classes, each one-standard-deviation increase in plasma polyunsaturated fatty acid (PUFA) levels was associated with a 21% reduced risk of overall GI cancer [hazard ratio (HR) per 1 standard deviation (1− SD) increase: 0.79; 95% confidence interval (CI): 0.71–0.87]. Cancer-specific analyses revealed significant risk reductions for esophageal (HR =0.68; 95% CI: 0.53–0.88), colorectal (HR =0.82; 95% CI: 0.70–0.95), and liver cancers (HR =0.66; 95% CI: 0.46–0.93). Subgroup analyses demonstrated stronger protective effects in males (HR =0.74), older adults (HR =0.73), and individuals with higher BMI (HR =0.81–0.82). Conversely, saturated fatty acids (SFAs) were positively associated with GI cancer risk. Conclusions: Elevated plasma PUFA levels are associated with reduced incidence of GI cancers, particularly in esophageal, colorectal, and liver cancers. These findings suggest that plasma PUFA measurements may facilitate the identification of high-risk subsets (e.g., males, older adults, individuals with obesity) and inform the development of biomarker-driven dietary guidelines for precision prevention. Randomized controlled trials are warranted to evaluate the efficacy of targeted PUFA supplementation in specific populations.
- 1 April 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (4) , 247
Open AccessPlasma fatty acid associated with risk of gastrointestinal cancer: a prospective cohort study from UK Biobank
Background: Gastrointestinal (GI) cancers represent a leading cause of cancer-related mortality worldwide, highlighting an urgent need for effective preventive approaches. While fatty acids (FAs) are implicated of carcinogenesis across multiple cancer types, their specific associations with GI cancer risk, and particularly their clinical utility as actionable biomarkers for risk stratification and personalized prevention within existing preventive frameworks, remain poorly understood. This study aimed to prospectively assess these associations and evaluate the clinical utility of plasma fatty acids for risk stratification and personalized prevention. Methods: This prospective cohort study included 91,239 cancer-free UK Biobank participants at baseline [2006–2010]. Plasma FAs were quantified using nuclear magnetic resonance (NMR) spectroscopy. Incident GI cancers [esophagus, stomach, colorectum, liver, bile duct, pancreas; International Classification of Diseases 10 (ICD-10) codes] were identified via national cancer registries through 2020. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) for incident GI cancers, with comprehensive adjustment for sociodemographic, lifestyle, and clinical covariates. Results: During a median follow-up of 11.8 years, 1,519 incident GI cancer cases were documented. Compared to non-cases, cases were older (mean age 60.8 vs. 55.5 years) and had a higher proportion of males (58.2% vs. 45.8%). After comprehensive adjustment for sociodemographic factors [age, sex, family history, educational level, Townsend deprivation index (TDI)], lifestyle characteristics (smoking, alcohol consumption, lifestyle score), clinical covariates [body mass index (BMI), diabetes history], and mutual correction for FA classes, each one-standard-deviation increase in plasma polyunsaturated fatty acid (PUFA) levels was associated with a 21% reduced risk of overall GI cancer [hazard ratio (HR) per 1 standard deviation (1− SD) increase: 0.79; 95% confidence interval (CI): 0.71–0.87]. Cancer-specific analyses revealed significant risk reductions for esophageal (HR =0.68; 95% CI: 0.53–0.88), colorectal (HR =0.82; 95% CI: 0.70–0.95), and liver cancers (HR =0.66; 95% CI: 0.46–0.93). Subgroup analyses demonstrated stronger protective effects in males (HR =0.74), older adults (HR =0.73), and individuals with higher BMI (HR =0.81–0.82). Conversely, saturated fatty acids (SFAs) were positively associated with GI cancer risk. Conclusions: Elevated plasma PUFA levels are associated with reduced incidence of GI cancers, particularly in esophageal, colorectal, and liver cancers. These findings suggest that plasma PUFA measurements may facilitate the identification of high-risk subsets (e.g., males, older adults, individuals with obesity) and inform the development of biomarker-driven dietary guidelines for precision prevention. Randomized controlled trials are warranted to evaluate the efficacy of targeted PUFA supplementation in specific populations.
- Open Access
- 3 January 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Noninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma
In pancreatic ductal adenocarcinoma (PDAC), the tumor immune microenvironment (TIME) is central to prognosis and therapeutic response, yet predictive biomarkers are still lacking. Here, we used PDAC patients from TCGA, CPTAC, and multiple centers to investigate and validate the relationship between the prognosis and tumor-infiltrating neutrophil-to-T-cell ratio (NTR) in the TIME, including the correlation of NTR with chemotherapy response in PDAC. We developed seven artificial intelligence models to evaluate NTR in the TIME, then evaluated their performance. The multi-modal ROI-model, designated PORCELAIN (Pancreatic Cancer Tumor-Infiltrating Neutrophil-to-T-Cell Ratio Evaluation with Artificial Intelligence), achieved superior external validation performance, demonstrating significant stratification of overall survival and recurrence-free survival. The NTR in the TIME is a potential biomarker for PDAC prognosis and treatment stratification. Importantly, PORCELAIN provides a noninvasive approach to assess NTR in the TIME, offering potential value for clinical management. Trial registration number: NCT06760234.
- 3 January 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Open AccessNoninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma
In pancreatic ductal adenocarcinoma (PDAC), the tumor immune microenvironment (TIME) is central to prognosis and therapeutic response, yet predictive biomarkers are still lacking. Here, we used PDAC patients from TCGA, CPTAC, and multiple centers to investigate and validate the relationship between the prognosis and tumor-infiltrating neutrophil-to-T-cell ratio (NTR) in the TIME, including the correlation of NTR with chemotherapy response in PDAC. We developed seven artificial intelligence models to evaluate NTR in the TIME, then evaluated their performance. The multi-modal ROI-model, designated PORCELAIN (Pancreatic Cancer Tumor-Infiltrating Neutrophil-to-T-Cell Ratio Evaluation with Artificial Intelligence), achieved superior external validation performance, demonstrating significant stratification of overall survival and recurrence-free survival. The NTR in the TIME is a potential biomarker for PDAC prognosis and treatment stratification. Importantly, PORCELAIN provides a noninvasive approach to assess NTR in the TIME, offering potential value for clinical management. Trial registration number: NCT06760234.
- Open Access
- 12 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-9
Early detection of G2SCH through machine learning analysis of physical examination metrics
Grade 2 subclinical hypothyroidism (G2SCH) is associated with an increased risk of various diseases but is rarely detected before symptom onset. This study aims to develop a machine learning-based prediction model for G2SCH using routine physical examination data. 57,539 samples were collected from one institution for training and 33,880 from another one for testing. Three feature-selecting methods were employed, while five machine learning algorithms were utilized. SHapley Additive exPlanation (SHAP) index of selected features were calculated. Area under curve (AUC), sensitivity and specificity were used to evaluate models. Our results demonstrate that the logistic regression model, using features selected by LASSO under a 65:35 SMOTENC ratio, achieved robust predictive performance with an AUC of 0.870 (95% CI: 0.834, 0.906), sensitivity of 86.8%, and specificity of 70.8%. We developed a high-performance machine learning model for G2SCH prediction based on physical examination data, enabling timely referral and appropriate treatment of G2SCH patients.
- 12 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-9
Open AccessEarly detection of G2SCH through machine learning analysis of physical examination metrics
Grade 2 subclinical hypothyroidism (G2SCH) is associated with an increased risk of various diseases but is rarely detected before symptom onset. This study aims to develop a machine learning-based prediction model for G2SCH using routine physical examination data. 57,539 samples were collected from one institution for training and 33,880 from another one for testing. Three feature-selecting methods were employed, while five machine learning algorithms were utilized. SHapley Additive exPlanation (SHAP) index of selected features were calculated. Area under curve (AUC), sensitivity and specificity were used to evaluate models. Our results demonstrate that the logistic regression model, using features selected by LASSO under a 65:35 SMOTENC ratio, achieved robust predictive performance with an AUC of 0.870 (95% CI: 0.834, 0.906), sensitivity of 86.8%, and specificity of 70.8%. We developed a high-performance machine learning model for G2SCH prediction based on physical examination data, enabling timely referral and appropriate treatment of G2SCH patients.
- Open Access
- 25 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e09987
Unraveling the Role of MDK‐SDC4 Interaction in Pancreatic Cancer‐Associated New‐Onset Diabetes by Single‐Cell Transcriptomic Analysis
Elevated blood glucose levels may serve as an early indicator of underlying pancreatic cancer. Discriminating between pancreatic cancer‐associated new‐onset diabetes (PCAND) and new‐onset type 2 diabetes mellitus (T2DM) holds promise for enabling an earlier diagnosis of pancreatic cancer. Nevertheless, the absence of effective biomarkers for distinguishing PCAND from the more prevalent new‐onset T2DM persists, primarily because of the elusive pathogenesis of PCAND. In this study, the intricate intercellular communication is comprehensively elucidated through single‐cell RNA sequencing. The findings identified Midkine (MDK) as a potential mediator of the interaction between tumor and beta cells. MDK, which originated from pancreatic ductal adenocarcinoma cells, exerted deleterious effects on paraneoplastic beta cells by binding to the SDC4 receptor on the beta cell surface and subsequently downregulating the Ras signaling pathway, thereby impairing insulin production and secretion. Notably, the plasma levels of MDK are higher in patients with PCAND than in those with T2DM. In conclusion, MDK has emerged as a pivotal driver of PCAND pathogenesis and may function as a blood‐based biomarker for discriminating between PCAND and T2DM in populations with new‐onset diabetes, thereby facilitating the advancement of early detection strategies for pancreatic cancer.
- 25 July 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e09987
Open AccessUnraveling the Role of MDK‐SDC4 Interaction in Pancreatic Cancer‐Associated New‐Onset Diabetes by Single‐Cell Transcriptomic Analysis
Elevated blood glucose levels may serve as an early indicator of underlying pancreatic cancer. Discriminating between pancreatic cancer‐associated new‐onset diabetes (PCAND) and new‐onset type 2 diabetes mellitus (T2DM) holds promise for enabling an earlier diagnosis of pancreatic cancer. Nevertheless, the absence of effective biomarkers for distinguishing PCAND from the more prevalent new‐onset T2DM persists, primarily because of the elusive pathogenesis of PCAND. In this study, the intricate intercellular communication is comprehensively elucidated through single‐cell RNA sequencing. The findings identified Midkine (MDK) as a potential mediator of the interaction between tumor and beta cells. MDK, which originated from pancreatic ductal adenocarcinoma cells, exerted deleterious effects on paraneoplastic beta cells by binding to the SDC4 receptor on the beta cell surface and subsequently downregulating the Ras signaling pathway, thereby impairing insulin production and secretion. Notably, the plasma levels of MDK are higher in patients with PCAND than in those with T2DM. In conclusion, MDK has emerged as a pivotal driver of PCAND pathogenesis and may function as a blood‐based biomarker for discriminating between PCAND and T2DM in populations with new‐onset diabetes, thereby facilitating the advancement of early detection strategies for pancreatic cancer.
- Open Access
- 24 March 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 16 (3) , 101236
Primary hepatic neuroendocrine tumor with a suspicious pulmonary nodule: A case report and literature review
BACKGROUND Primary hepatic neuroendocrine tumors (PHNETs) are extremely rare tumors originating from neuroendocrine cells. Due to lack of neuroendocrine symptoms and specific radiographic characteristics, PHNETs are challenging to differentiate from other liver tumors. CASE SUMMARY This case involved a 67-year-old male who was admitted with a discovered hepatic mass and a suspicious lung lesion. Primary hepatic carcinoma was initially speculated based on the characteristic magnetic resonance imaging findings. The patient underwent a laparoscopic right partial hepatectomy, and subsequent immunohistochemical examination revealed a HNET. To exclude other potential origins, a positron emission tomography-computed tomography scan and gastrointestinal endoscopy were performed, leading to a final diagnosis of PHNETs. Then we conducted a literature review using the PubMed database, identifying 99 articles and 317 cases related to PHNETs. The characteristics, diagnostic methods, and treatment of PHNETs have been described. Finally, we elaborate on the presumed origins, pathological grades, clinical features, diagnosed methods, and treatments associated with PHNETs. CONCLUSION The diagnosis of PHNETs was primarily an exclusionary process. A definitive diagnosis of PHNETs relied mainly on immunohistochemical markers (chromogranin A, synaptophysin, and cluster of differentiation 56) and exclusion of primary foci in other organs. Radical surgery was the preferred treatment for early-stage tumors.
- 24 March 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 16 (3) , 101236
Open AccessPrimary hepatic neuroendocrine tumor with a suspicious pulmonary nodule: A case report and literature review
BACKGROUND Primary hepatic neuroendocrine tumors (PHNETs) are extremely rare tumors originating from neuroendocrine cells. Due to lack of neuroendocrine symptoms and specific radiographic characteristics, PHNETs are challenging to differentiate from other liver tumors. CASE SUMMARY This case involved a 67-year-old male who was admitted with a discovered hepatic mass and a suspicious lung lesion. Primary hepatic carcinoma was initially speculated based on the characteristic magnetic resonance imaging findings. The patient underwent a laparoscopic right partial hepatectomy, and subsequent immunohistochemical examination revealed a HNET. To exclude other potential origins, a positron emission tomography-computed tomography scan and gastrointestinal endoscopy were performed, leading to a final diagnosis of PHNETs. Then we conducted a literature review using the PubMed database, identifying 99 articles and 317 cases related to PHNETs. The characteristics, diagnostic methods, and treatment of PHNETs have been described. Finally, we elaborate on the presumed origins, pathological grades, clinical features, diagnosed methods, and treatments associated with PHNETs. CONCLUSION The diagnosis of PHNETs was primarily an exclusionary process. A definitive diagnosis of PHNETs relied mainly on immunohistochemical markers (chromogranin A, synaptophysin, and cluster of differentiation 56) and exclusion of primary foci in other organs. Radical surgery was the preferred treatment for early-stage tumors.
- Open Access
- 12 December 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (12) , e70220
Surgical Resection Enhances Survival in Patients With Liver Metastases From Gastric Cancer: A Population‐Based, Case‐Control Study
Background and Aims: Gastric cancer with liver metastases (GCLM) is a challenging condition that significantly reduces long‐term survival rates, but recent advancements in surgical techniques have shown promise. This study aims to comprehensively evaluate the impact of surgical resection on survival rates in GCLM patients.Methods: We conducted a population‐based analysis utilizing the SEER database for patients diagnosed with GCLM between 2010 and 2015. Overall survival (OS) was compared between patients who underwent cancer‐directed surgery (CDS) and those who did not. The overlap weighting method based on lasso regression with penalty factors was employed to minimize selection bias. Survival outcomes were compared using Kaplan‐Meier curves and Cox proportional hazards models, with subgroup analyses to further explore the effects of surgery among patients.Results: A total of 3694 patients with GCLM were identified. Of those, 354 (9.58%) patients underwent CDS. After propensity score adjustment, The median OS was significantly higher in the surgical resection group (12 months, 95% confidence interval (CI) 11–16) compared to the nonresection group (6 months, 95% CI: 5–6). Cox regression analysis revealed a substantial improvement in OS for the surgical resection group, with a hazard ratio (HR) of 0.562 (95% CI: 0.482–0.656), including patients with adverse conditions.Conclusions: The analysis demonstrated a clear association between surgical resection and enhanced OS in GCLM patients. Nevertheless, further research endeavors should be undertaken to identify specific prognostic factors that aid in the selection of optimal candidates for surgical resection.
- 12 December 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (12) , e70220
Open AccessSurgical Resection Enhances Survival in Patients With Liver Metastases From Gastric Cancer: A Population‐Based, Case‐Control Study
Background and Aims: Gastric cancer with liver metastases (GCLM) is a challenging condition that significantly reduces long‐term survival rates, but recent advancements in surgical techniques have shown promise. This study aims to comprehensively evaluate the impact of surgical resection on survival rates in GCLM patients.Methods: We conducted a population‐based analysis utilizing the SEER database for patients diagnosed with GCLM between 2010 and 2015. Overall survival (OS) was compared between patients who underwent cancer‐directed surgery (CDS) and those who did not. The overlap weighting method based on lasso regression with penalty factors was employed to minimize selection bias. Survival outcomes were compared using Kaplan‐Meier curves and Cox proportional hazards models, with subgroup analyses to further explore the effects of surgery among patients.Results: A total of 3694 patients with GCLM were identified. Of those, 354 (9.58%) patients underwent CDS. After propensity score adjustment, The median OS was significantly higher in the surgical resection group (12 months, 95% confidence interval (CI) 11–16) compared to the nonresection group (6 months, 95% CI: 5–6). Cox regression analysis revealed a substantial improvement in OS for the surgical resection group, with a hazard ratio (HR) of 0.562 (95% CI: 0.482–0.656), including patients with adverse conditions.Conclusions: The analysis demonstrated a clear association between surgical resection and enhanced OS in GCLM patients. Nevertheless, further research endeavors should be undertaken to identify specific prognostic factors that aid in the selection of optimal candidates for surgical resection.
- Open Access
- 11 November 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (21) , e70388
Predicting Pancreatic Cancer in New‐Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large‐Scale Prospective Cohort Study
Introduction: Individuals who develop new‐onset diabetes have been identified as a high‐risk cohort for pancreatic cancer (PC), exhibiting an incidence rate nearly 8 times higher than the general population. Hence, the targeted screening of this specific cohort presents a promising opportunity for early pancreatic cancer detection. We aimed to develop and validate a novel model capable of identifying high‐risk individuals among those with new‐onset diabetes. Methods: Employing the UK Biobank cohort, we focused on those developing new‐onset diabetes during follow‐up. Genetic and clinical characteristics available at registration were considered as candidate predictors. We conducted univariate regression analysis to identify potential indicators and used a 5‐fold cross‐validation method to select optimal predictors for model development. Five machine learning algorithms were used for model development. Results: Among 12,735 patients with new‐onset diabetes, 100 (0.8%) were diagnosed with PC within 2 years. The final model (area under the curve, 0.897; 95% confidence interval, 0.865–0.929) included 5 clinical predictors and 24 single nucleotide polymorphisms. Two threshold cut‐offs were established: 1.28% and 5.26%. The recommended 1.28% cut‐off, based on model performance, reduces definitive testing to 13% of the total population while capturing 76% of PC cases. The high‐risk threshold is 5.26%. Utilizing this threshold, only 2% of the population needs definitive testing, capturing nearly half of PC cases. Conclusions: We, for the first time, combined clinical and genetic data to develop and validate a model to determine the risk of pancreatic cancer in patients with new‐onset diabetes using machine learning algorithms. By reducing the number of unnecessary tests while ensuring that a substantial proportion of high‐risk patients are identified, this tool has the potential to improve patient outcomes and optimize healthcare sources.
- 11 November 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (21) , e70388
Open AccessPredicting Pancreatic Cancer in New‐Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large‐Scale Prospective Cohort Study
Introduction: Individuals who develop new‐onset diabetes have been identified as a high‐risk cohort for pancreatic cancer (PC), exhibiting an incidence rate nearly 8 times higher than the general population. Hence, the targeted screening of this specific cohort presents a promising opportunity for early pancreatic cancer detection. We aimed to develop and validate a novel model capable of identifying high‐risk individuals among those with new‐onset diabetes. Methods: Employing the UK Biobank cohort, we focused on those developing new‐onset diabetes during follow‐up. Genetic and clinical characteristics available at registration were considered as candidate predictors. We conducted univariate regression analysis to identify potential indicators and used a 5‐fold cross‐validation method to select optimal predictors for model development. Five machine learning algorithms were used for model development. Results: Among 12,735 patients with new‐onset diabetes, 100 (0.8%) were diagnosed with PC within 2 years. The final model (area under the curve, 0.897; 95% confidence interval, 0.865–0.929) included 5 clinical predictors and 24 single nucleotide polymorphisms. Two threshold cut‐offs were established: 1.28% and 5.26%. The recommended 1.28% cut‐off, based on model performance, reduces definitive testing to 13% of the total population while capturing 76% of PC cases. The high‐risk threshold is 5.26%. Utilizing this threshold, only 2% of the population needs definitive testing, capturing nearly half of PC cases. Conclusions: We, for the first time, combined clinical and genetic data to develop and validate a model to determine the risk of pancreatic cancer in patients with new‐onset diabetes using machine learning algorithms. By reducing the number of unnecessary tests while ensuring that a substantial proportion of high‐risk patients are identified, this tool has the potential to improve patient outcomes and optimize healthcare sources.
- Open Access
- 29 June 2023
- Published by Springer Nature in Research Square
Does Surgical Resection Improve the Survival of Patients with Gastric Cancer Liver Metastases? A Population-Based, Propensity Score–Adjusted Analysis
Purpose The use of surgery in the management of patients with gastric cancer liver metastases (GCLM) has been debatable. We aimed to assess whether surgical resection is associated with improved patient survival.Methods Patients with GCLM were identified in the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Adult gastric cancer patients (aged ≥ 18 years) with liver metastases living longer than one month were eligible for this analysis. The overlap weighting method based on lasso regression with penalty factors (OW_pLasso) was applied to reduce the selection bias. The survival times of patients who underwent surgery and those who did not were compared using OW_pLasso adjusted Kaplan-Meier curves and Cox proportional hazards models.Results A total of 3694 patients with GCLM were identified. Of those, 354 (9.58%) patients underwent cancer-directed surgery (CDS). After OW_pLasso adjustment, the median overall survival was 12 months [95% confidence interval (CI) 11–16] in the CDS group and 6 months [95% CI 5–6] in the Non-CDS group. In Cox regression analysis, primary cancer resection was associated with a significantly better overall survival [hazard ratio (HR) 0.562, 95% confidence interval (CI) 0.482–0.656]. The benefit of surgical resection persisted in patients with worse conditions (large size and high-grade tumors, advanced T stages, and limited lymph node metastases).Conclusions In this population-based cohort analysis of patients with gastric cancer and liver metastases, surgical resection was linked to a better overall survival. As a result, surgery has the potential to be an option for treating patients with liver metastases.
- 29 June 2023
- Published by Springer Nature in Research Square
Open AccessDoes Surgical Resection Improve the Survival of Patients with Gastric Cancer Liver Metastases? A Population-Based, Propensity Score–Adjusted Analysis
Purpose The use of surgery in the management of patients with gastric cancer liver metastases (GCLM) has been debatable. We aimed to assess whether surgical resection is associated with improved patient survival.Methods Patients with GCLM were identified in the Surveillance, Epidemiology, and End Results database between 2010 and 2015. Adult gastric cancer patients (aged ≥ 18 years) with liver metastases living longer than one month were eligible for this analysis. The overlap weighting method based on lasso regression with penalty factors (OW_pLasso) was applied to reduce the selection bias. The survival times of patients who underwent surgery and those who did not were compared using OW_pLasso adjusted Kaplan-Meier curves and Cox proportional hazards models.Results A total of 3694 patients with GCLM were identified. Of those, 354 (9.58%) patients underwent cancer-directed surgery (CDS). After OW_pLasso adjustment, the median overall survival was 12 months [95% confidence interval (CI) 11–16] in the CDS group and 6 months [95% CI 5–6] in the Non-CDS group. In Cox regression analysis, primary cancer resection was associated with a significantly better overall survival [hazard ratio (HR) 0.562, 95% confidence interval (CI) 0.482–0.656]. The benefit of surgical resection persisted in patients with worse conditions (large size and high-grade tumors, advanced T stages, and limited lymph node metastases).Conclusions In this population-based cohort analysis of patients with gastric cancer and liver metastases, surgical resection was linked to a better overall survival. As a result, surgery has the potential to be an option for treating patients with liver metastases.